Rugby Patent-Cliff Exposure & CMS Drug Spending Portfolio

Rugby (US): 86 reconciled FDA prescription therapies, $54.0M 2024 CMS Part D & Medicaid spend, and $5,647 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies86
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$54.0M
2024 Medicare Part D Spend$339
2024 Medicaid Spend$54.0M
California HCAI SB 17 FilingsSpecialty launch notice ($5,647 intro WAC)